AstraZeneca: EU approves Enhertu for breast cancer

(CercleFinance.com) - AstraZeneca announces that Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy or who develop recurrent disease during or within six months of completing adjuvant chemotherapy.


For the record, Enhertu is an antibody-drug conjugate (ADC) jointly developed and marketed by AstraZeneca and Daiichi Sankyo.

The approval by the European Commission follows a positive opinion from the Committee for Medicinal Products for Human Use and is based on the results of a phase III trial showing that Enhertu reduced the risk of disease progression or death by 50% and increased overall survival by over 6 months compared to chemotherapy.


Copyright (c) 2023 CercleFinance.com. All rights reserved.